Goelzer Investment Management Inc. Has $263,000 Position in Becton, Dickinson and Company (NYSE:BDX)

Goelzer Investment Management Inc. increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.4% during the 4th quarter, Holdings Channel reports. The institutional investor owned 1,159 shares of the medical instruments supplier’s stock after acquiring an additional 100 shares during the quarter. Goelzer Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $263,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Livelsberger Financial Advisory acquired a new position in shares of Becton, Dickinson and Company during the third quarter worth $26,000. Ashton Thomas Securities LLC acquired a new position in Becton, Dickinson and Company during the 3rd quarter worth about $33,000. Tompkins Financial Corp lifted its holdings in Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 46 shares during the period. Sound Income Strategies LLC increased its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the third quarter worth about $46,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BDX. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Evercore ISI boosted their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $283.50.

Becton, Dickinson and Company Stock Performance

NYSE:BDX opened at $243.69 on Friday. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $248.42. The company has a fifty day moving average of $228.08 and a 200-day moving average of $233.00. The firm has a market capitalization of $70.67 billion, a P/E ratio of 41.02, a P/E/G ratio of 1.72 and a beta of 0.39.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.42 earnings per share. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.42 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, December 9th. This represents a $4.16 annualized dividend and a yield of 1.71%. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. Becton, Dickinson and Company’s dividend payout ratio is presently 70.03%.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Michael David Garrison sold 597 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $236.51, for a total transaction of $141,196.47. Following the sale, the executive vice president now directly owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. The trade was a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,844 shares of company stock valued at $2,210,716. Company insiders own 0.36% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.